Importantly, the authors could show that the applied nanobodies neither induced anti-drug antibodies (ADAs) nor did they enhance pre-existing ADAs which were found in only low amounts in 1 out of 20 breast carcinoma patients. This evidence concerns the gene AGPS and breast carcinoma.